FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	$D \subset$	20540	
vasililigion,	D.C.	20349	

STATEMENT	OF	<b>CHANGES</b>	IN BE	NEFICIAL	OWN	ERSHIP

	OMB APP	ROVAL								
	OMB Number: 3235-028									
	Estimated average burden hours per response: 0.									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Alpern Robert J				2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ ABBV ]							Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last) 1 N. WA	(Fi UKEGAN l	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/31/2022								(give title		ther (s <sub>l</sub> low)	pecify
(Street) NORTH CHICAG	O IL	(	60064	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				1
(City)	(St	ate) (	(Zip)													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
		Date	ransaction e nth/Day/Yea	Execution		n Date	r, Transaction Dispo		urities Acquired (A) eed Of (D) (Instr. 3, 4		Benefici	es ally Following	6. Ownersh Form: Direct (D) or Indirect (I) (Instr. 4)	n: Direct or Indirect Enstr. 4)	7. Nature of Indirect Beneficial Ownership	
						Code V	Amoun	t (A) o	r Price	Transaci (Instr. 3	tion(s)			(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Conversion or Exercise Price of Derivative Security			Code (	Transaction of E Code (Instr. Derivative (I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owner Form Direct or Ind (I) (In	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Equivalent Units	\$162.11	03/31/2022		A		44		(1)	(1)	Common Stock	44	\$162.11	8,335 <sup>(2)</sup>	) ]	)	

## **Explanation of Responses:**

- 1. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
- 2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Steven L. Scrogham, attorneyin-fact for Robert J. Alpern

04/04/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.